Is Dementia Screening of Apparently Healthy Individuals Justified?

Larry W. Chambers, Saskia Sivananthan, and Carol Brayne

1 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada
2 Bruyère Research Institute, Ottawa, ON, Canada
3 Faculty of Health, York University, Toronto, ON, Canada
4 Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
5 Primary Health Services Division, Alberta Health Services, Edmonton, AB, Canada
6 Cambridge Institute of Public Health, School of Clinical Medicine, University of Cambridge, Cambridge, UK

Correspondence should be addressed to Larry W. Chambers; chambers@mcmaster.ca

Received 24 January 2017; Revised 1 June 2017; Accepted 14 June 2017; Published 8 August 2017

1. Introduction

Dementia is a condition with multiple causes that affects memory, other cognitive abilities, and behaviour that interfere with a person's ability to drive, deal with their finances, manage their healthcare, and live independently [1]. Also, dementia has a significant impact not only on individuals but also on their careers, families, communities, and societies [2].

Alzheimer's disease and vascular dementia are the most common forms of dementia and other causes are dementia with Lewy bodies and a group of diseases that contribute to frontotemporal dementia [2]. In 2015, dementia affected 47 million people worldwide, that is estimated to increase to 75 million in 2030 and 132 million by 2050 [3]. Recent reviews estimate that globally nearly 9.9 million people develop dementia each year [3].

Though age is by far the strongest known risk for the onset of the common dementias, not all older adults develop dementia. Also, younger adults develop dementia (defined as the onset of symptoms before the age of 65 years) accounting for less than 9% of cases [2].

Risk reduction and maintenance of cognitive abilities is known to be associated with particular behaviours and environments, similar to other long-term diseases [4]. Dementia risk is lower for people who have been physically active, avoided overweight, had balanced diets, did not smoke, and had moderate use of alcohol as well as avoiding and managing specific conditions such as high blood pressure, stroke, and diabetes mellitus [4].
Table 1: Six testing, clinical, and economic conditions for determining whether screening for dementia among “apparently” healthy individuals does more good than harm.

| Dementia tests |
|----------------|
| (i) How feasible is it to accurately identify individuals with high likelihood of dementia via screening tests? |
| (ii) What is the estimated prevalence of dementia in the population to be screened? |

| Clinical issues |
|-----------------|
| (i) Is the clinical course of dementia amenable to intervention and if yes at what stage and is their adequate evidence? |
| (ii) What are the reasons and value of an individual knowing a diagnosis of dementia? |

| Economic issues |
|-----------------|
| (i) Does the healthcare system have the capacity to respond to increased demand resulting from screening for dementia? |
| (ii) Will screening add value to individuals with dementia, the healthcare system, and society? |

In our view, there is a profound disconnect between the assertions of some researchers and journals and the wider practitioner and other researcher clinician communities that healthy populations be screened for dementia to identify individuals with dementia early [5–8]. “Early” here includes screening in situations where neither the individual nor his/her caregiver have noticed any symptoms, or have judged, or recognised them, as needing clinical assessment. “Healthy” here refers to the WHO definition, “the extent to which an individual or group is able to realize aspirations and satisfy needs, and to change or cope with the environment. Health is a resource for everyday life, not the objective of living; it is a positive concept, emphasizing social and personal resources, as well as physical capacities” [9].

While the motivation for screening is well intentioned, four recent reports [10–13] by expert panels that systematically reviewed the dementia screening evidence recommend not screening individuals who are not themselves, or their families, seeking such attention (Recent Reviews on Dementia Screening). We think that the following case example can help illustrate different perspectives and assessment of the balance of potential benefit and harm.

Recent Reviews on Dementia Screening. See [10–13].

2. Case Presentation (Hypothetical)

The local Alzheimer Association requested advice from the local medical society to introduce an awareness raising campaign to screen for dementia. Practitioners often see individuals who once diagnosed have a clear view that their delay in accessing support and advice from services have caused harm and that this can be remedied by systematic screening. They feel that early detection and remediation could lead to improved quality of life for affected individuals and their caregivers. The Alzheimer Association states that their supports and other activities are available for any individuals with identified problems. They believe that making the test results known to caregivers and the Association will assist individuals when identified early. Many jurisdictions have begun such campaigns and are enthusiastic about them. Concerned caregivers in your community are encouraging the Alzheimer Association to follow suit. You are part of a committee asked by the medical society to prepare an answer. Your report will be due next week.

3. Use of Critical Appraisal to Assist in Deciding Whether or Not to Screen

Public resources are involved in this decision. Funding used for one activity is not then available for another. Deciding to screen or not should therefore be based on explicit criteria. A collection of previous experiences and the evolution of rules of evidence about screening [14] were fused into the three following areas: testing, clinical decisions, and economic considerations. These criteria can be used to determine, on the basis of current evidence, whether screening causes more harm than good in individuals who have not sought medical attention. The rest of this article will describe these and show how to use them when appropriate for a given population (Table 1).

4. Dementia Tests

4.1. How Feasible Is It to Accurately Identify Individuals with High Likelihood of Dementia via Screening?

Psychometric properties differ according to populations and settings (community, tertiary, secondary, and primary care). The test quality for dementia is influenced by many factors that include age, culture, occupation, education, environmental context, and health variables (medications, delirium, and depression).

A recent systematic review reported 22 short validated cognitive tests [15], so practitioners have to consider which to use and interpret the results, taking into account the setting and the individual patient’s premorbid education, language and literacy skills and any current motor, and hearing and visual impairment. For example, two dementia screening tests used by primary care practitioners for apparently healthy individuals are the Mini Mental State Examination [16] and the Montreal Cognitive Assessment [17]. However, as many as 1 in 8 healthy individuals screened for dementia and mild cognitive impairment are incorrectly classified using the MMSE. As many as 1 in 4 are screened incorrectly using the MoCA [12, 18, 19]. This level of “false positives” can cause harm from an emotional health and practical stand point.
some jurisdictions, a diagnosis for dementia may cause denial of health insurance and may affect an individual’s right to drive (see also Section 6.2 below).

Tests for dementia are just the beginning of the process required to arrive at a diagnosis of dementia. Features and typical trajectories of dementia include an understanding of the differences between expected changes and ones that signal deficits related to disability. Test interpretation requires acknowledging the wide variability in changes in cognitive ability over time, in older adults. In addition, medication, including polypharmacy, and comorbid conditions must be taken into consideration. In usual older people the “normal ranges” of cognitive tests have not been tested in whole populations. Screening tests applied in clinics will not perform in the same way in different population settings (see Section 4.2. below).

The diagnosis of dementia must rule out treatable conditions that contribute to cognitive deficits and declines. These include sleep apnea, hypothyroidism, depression, polypharmacy, delirium, and declines in vision and hearing. If a primary care team screen targeted groups who, themselves or their families/community, have not sought help for any concerns and are aged 80 years and over the process will identify many other conditions: high blood pressure (41%), depression (32%), heart disease (27%), transient ischaemic attack (18%), and diabetes (13%) [20].

4.2. What Is the Estimated Prevalence of Dementia in the Population To Be Screened? Positive predictive value (PPV) is the probability that a positive test result is correct in those who test positive. The prevalence of dementia in the population being screened has a dramatic impact on the PPV of a test, even if there is consistent sensitivity and specificity. As shown in Figure 1(a) (Table 2), in a locked unit in a long-term care home, where the prevalence of dementia is 80%, regardless of the accuracy of the test, the PPV is 97%. In a Memory Clinic where the prevalence of dementia is 30%, the PPV of the test is 77% (using the same test with equal sensitivity and specificity) (Figure 1(b)) (Table 2). Even in this setting 1/4 people will receive the possibility that their positive screening is wrong. Prevalence of dementia is ~6% [21] in the general population or in a primary care clinic and this results in the PPV of the test dropping to 34% even with the sensitivity and specificity being held steady (Figure 1(c)) (Table 2). This means that between 6 and 7 people out of every 10 who tested positive will not then be diagnosed as demented.

Primary and community care settings involve screening thousands of individuals. Figure 1(c) demonstrates that 10% of individuals screened in these settings will be mislabeled. The number mislabeled would be 100,000 if a million individuals were screened in the general population or in a primary care clinic. However, “...the magnitude of these figures in even an opportunistic screening program result in problems not only at the primary care level but also on the specialist level to handle the volumes of people with a suspected cognitive impairment” [22].

Between 1997 and 2011, incentives in the UK lead to a dramatic increase in the number of referrals, but it led to no increase in the prevalence of dementia [23]. However, in 2014, the United Kingdom Department of Health introduced a £5 incentive for general practice physician offices to screen and diagnose dementia [24]. Memory Disorder Clinics reported having more individuals with functional memory problems and an increase in persons with depression following this policy. Testing of low B12 and folate levels consistently occurred. Mood testing only occurred in 26% of the population being screened for dementia despite knowledge that depression is a common and treatable risk factor for dementia [25]. In 2016, the monetary incentive for general practice physicians in the United Kingdom to screen and diagnose dementia was phased out.

An alternative argument to screening for dementia among apparently healthy older adults has been put forward to screen for general well-being [26]. Here the argument is that the evidence shows that older adults with higher well-being are able to adapt their psychological well-being to numerous impairments and diseases [27, 28]. The resilience and flexibility to adapt are the norm up to very old age,
### Care settings:

#### (a) Impact of memory testing in a locked unit in a care home in mislabelling of dementia

- **Number of people memory test labelled as having memory deficit: (hypothetical test sensitivity = 80%, specificity = 90%)**
- **% with dementia (truth):**
- **Care settings:**
  - 100 people seen in a locked unit in a care home
  - **80%**
- **All 100 complete memory test**
- **66 labelled as “dementia”**
- **2 Mislabelled**
- **64 Labelled correctly**

(i) Do not have dementia but continue to receive care in a locked unit in a care home

See Table 2 for table showing calculations

#### (b) Impact of memory testing in memory disorder clinics in mislabelling of dementia

- **Number of people memory test labelled as having memory deficit: (hypothetical test sensitivity = 80%, specificity = 90%)**
- **% with dementia (truth):**
- **Care settings:**
  - 100 people seen in a Memory Disorder Clinic
  - **30%**
- **All 100 complete memory test**
- **31 labelled as “dementia”**
- **7 Mislabelled**
- **24 Labelled correctly**

(i) Anxious people with “dementia” label
(ii) Clinic initiates diagnostic work-up

See Table 2 for table showing calculations

#### (c) Impact of memory testing in family physician’s offices in mislabelling of dementia

- **Number of people memory test labelled as having memory deficit: (hypothetical test sensitivity = 80%, specificity = 90%)**
- **% with dementia (truth):**
- **Care settings:**
  - 100 people seen in a family physician’s office
  - **6%**
- **All 100 complete memory test**
- **14 labelled as “dementia”**
- **10 Mislabelled**
- **4 Labelled correctly**

(i) Anxious people with “dementia” label
(ii) Risk of unnecessary treatment
(iii) Family physician initiates diagnostic work-up

See Table 2 for table showing calculations

---

**Table 2**

| Care setting | Mislabelled | Labelled correctly |
|--------------|-------------|--------------------|
| Locked unit  | 2           | 64                 |
| Memory Disorder Clinic | 7 | 24                 |
| Family Physician’s Office | 10 | 4                  |

---

**Figure 1**
5. Clinical Issues

5.1. Is the Clinical Course of Dementia Amenable to Intervention and If Yes at What Stage and Is There Adequate Evidence? Most common dementias are attributed to a combination of Alzheimer’s type and vascular pathologies [30,31]. The average age of onset of dementia is in a person’s early 80s [21]. Mild stages of dementia are being identified increasingly in clinical practice, with a drift toward predementia diagnosis at younger ages.

Screening should occur after any condition’s biologic onset but before usual diagnosis and treatment to improve the course of consequences of having the condition. The prerequisite assumption is that screening for dementia among previously undiagnosed individuals leads to improvement in quality of life vis-à-vis unscreening individuals (Figure 2).

Although very important for decision-making about interventions, the stages of dementia (mild, moderate, and severe) lack clinical consensus and therefore the stage of dementia is not routinely reported by clinicians. The pathology accompanying dementia among older individuals is complex [32–36]. New research on biomarkers may or may not change this situation.

Screening of apparently healthy individuals is only justified if there is an effective treatment for specific conditions identified. Screening of populations or groups before symptoms develop is clearly not justified at present as there is no drug that arrests clinically diagnosed dementia of the Alzheimer’s type. Clinical trials of cholinesterase inhibitors have not been shown to improve the symptoms of dementia with individuals who have mild cognitive impairments [10]. In addition, the substantial number of withdrawals from trials suggests intolerance to these drugs [37]. As many as 40% of individuals assessed as ‘mild cognitive impairment no dementia’ may remain the same in the following five years and many improve [38, 39].

5.2. What Are the Reasons and Value of an Individual Knowing a Diagnosis of Dementia? Some argue that screening of apparently healthy individuals is a process that is independent of the evidence of effectiveness of screening but more a “right to know” about the condition. The “right to know” a diagnosis [40] assumes the existence of a precise definition of the condition. An understanding of the condition and the underlying reasons in its clinical course and the clinical course for the person, their age, and gender is also assumed. The assumption continues with the impact of contextual factors such as comorbidity, ethnicity, and education as well as, in the case of dementia, relationship to end of life. Prognostication is one aspect of a diagnosis, but even superficial consideration of the current evidence highlights the lack of a sufficient evidence base to inform such a justification for a diagnosis through screening of apparently healthy individuals [41]. More research is warranted before any further calls for dementia screening of populations.

Prognosis with the dementias and predementia states is already beset with uncertainty, even within a usual clinical setting. Rarely is an individual provided with the scale and range of uncertainty. Where prognosis is being imposed on a previously undiagnosed individual through opportunistic application of a screening test, it would seem important that they are informed of the degree of uncertainty about prognosis of testing positive. This parallels with breast cancer screening where public awareness of overdiagnosis and overtreatment is growing [42, 43].

Screening leads to some misdiagnosis and overdiagnosis for individuals including the harmful effects of diagnosis, implications of taking diagnostic processes further, and overtreatment. The consequences of dementia testing could include being inaccurately labelled, stigmatization, premature curtailment of employment, and loss of support for day-to-day functions, such as driving, remaining independent, and making financial and healthcare decisions [44, 45].

6. Economic Issues

6.1. Does the Healthcare System Have the Capacity to Respond to Increased Demand Resulting from Screening for Dementia? Healthcare system challenges required to respond to increased prevalence are likely to be substantial. For example, primary care costs and specialist costs of diagnosing dementia far exceed costs of diagnosing other common chronic conditions for which diagnostic markers are available (e.g., hypertension). This is a small fraction of the lifetime costs of care incurred by an individual with dementia [46].

Dramatic increases in memory clinic referrals following increased screening of “apparently healthy” individuals creates challenges for health and social services [10–13]. Unimpaired and worried individuals may be kept under follow-up which uses up staff resources. This overburdening of existing systems violates one of the principles of screening. Opportunity costs can include fewer resources for those individuals diagnosed with dementia because of underresourced and poorly coordinated health and social care that involves multiple agencies and practitioners [47].

6.2. Will Screening Add Value to Individuals with Dementia, the Healthcare System, and Society? Many members of the
public believe that a treatment exists to reduce the existing symptoms and effectively slow its progression. A significant proportion believe that a reliable medical test to diagnose dementia is currently available [48]. The reality is that diagnosis is not always straightforward and there is no drug to stop most causes of dementia [49]. There is a degree of uncertainty that should be shared and understood that the process of diagnosis has a number of uncertainties. This uncertainty is increased because of the connection between cognitive ability, neurobiology, ageing, end of life, and clinical course for an individual. Informed consent is difficult to achieve with this kind of uncertainty.

Recent studies of populations are revealing new concerns about the value of screening to identify early dementia. If referred to a specialist, an individual is twice as likely to be institutionalized [50]. After the first year for people newly diagnosed with dementia, 65% will be transferred from institution to institution, usually acute care hospitals, at least once and 17% will have three or more healthcare practitioner transitions [51]. These transitions can increase the risk of medication errors, hospital readmissions, and deaths. When receiving antipsychotic or benzodiazepine medications or living in a rural area, the transitions increase. Older adults receiving newly started cholinesterase inhibitor drug therapy have more physicians providing care and have higher anticholinergic drug burden scores [52]. These studies raise questions about the importance of the psychosocial environment surrounding the person with dementia. This includes domains of social networks (number of caregivers involved in care decisions) or personality traits (self-care behaviour, being unaware of cognitive inability) that may influence both care referral and the clinical evolution. Overdiagnosis of dementia is harmful and can interfere with a good quality of life because of the altered self-perception and perception of others as well as stigmatization, early institutionalization, side effects of medications, and premature shutdown of regular life activities [42–45].

7. Case Conclusion

The medical society group that was advising the local Alzheimer Association about the proposed community wide awareness campaign on dementia screening examined the evidence about the links of “apparently healthy” individuals. It concluded that there were few interventions of rigorously demonstrated efficacy for the symptoms of dementia that would be detected among apparently healthy individuals, and there was no acceptable evidence that the early detection of most of the symptoms of dementia altered their prognoses. The required studies simply had not been done indicating the need for more research on the six questions outlined in this report.

The committee shared the caregivers and the Alzheimer Association concerns that a substantial burden of morbidity affecting individuals, their caregivers, and the whole community resulted from dementia.

The measurement properties of the available and feasible screening tests were largely unknown in primary care settings.

Moreover, it was judged that the oldest, old individuals who were at the greatest risk for dementia, would be most likely the group that might benefit from dementia screening. The committee questioned whether dementia screening of apparently healthy individuals was the best use of existing Alzheimer Association and other specialized services. The committee’s final recommendation was that the resources available for the community-wide awareness campaign on dementia screening should be used for research to generate evidence on dementia screening in the community.

Additional Points

Considerable investment has been made by many societies to raise awareness of dementia, including exhortations for screening by some. Four recent reports by expert panels that systematically reviewed the evidence about screening for dementia and recommend not screening individuals who are not themselves, or their families, seeking such attention. Current evidence on testing, clinical decisions, and economic considerations can be evaluated to estimate whether screening could cause more harm than good in individuals who have not presented for medical attention and may have no symptoms. Considerable resources are currently being used for dementia screening without an evidence base and should be redirected and restructured to generate evidence on dementia screening in the community and selected settings.

Disclosure

Views or opinions presented in this manuscript are solely those of the authors and do not necessarily represent those of their organizations. This manuscript was based on presentations by Drs. Brayne and Chambers at the session entitled “Does Dementia Screening Lead to Over-Diagnosis or an Opportunity for Early Intervention?” during the Alzheimer Association International Conference, held in Copenhagen, in July, 2014.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All three authors made substantial contributions to the conception, design, acquisition, analysis, or interpretation of data for the work. All three authors drafted the work or revised it critically for important intellectual content. All three authors have given their final approval of this version to be published. All three authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

[1] D. G. Blazer, K. Yaffe, and C. T. Liverman, Eds., IOM (Institute of Medicine), Cognitive Aging: Progress in Understanding
and Opportunities for Action, The National Academies Press, Washington, DC, USA, 2015.

[12] Alzheimer’s Association, “2016 Alzheimer’s disease facts and figures,” Alzheimer’s and Dementia, vol. 12, no. 4, pp. 459–509, 2016.

[13] Alzheimer’s Disease International, Dementia Statistics, 2017, http://www.alz.co.uk/research/statistics.

[14] Alzheimer’s Disease International, World Alzheimer Report 2014: Dementia and Risk Reduction, 2017, http://www.alz.co.uk/research/world-report-2014.

[15] J. C. Morris, J. Weng, and C. Xiong, “Subjective Cognitive Decline Versus Informant Report,” in Proceedings of the Alzheimer Association International Conference 2014 Screening for Alzheimer’s Disease in Cognitively Normal Older Adults, vol. 10, https://deepdyve.com/lp/elsevier/screening-for-alzheimer-s-disease-inhttps://www.deepdyve.com/lp/elsevier/screening-for-alzheimer-s-disease-in-cognitively-normal-other-adults-rJ1kXhjBa0cognitively-normal-other-adults-rJ1kXhjBa0.

[16] B. Dubois, S. Epelbaum, A. Michon et al., “Screening for AD: Why and How?” in Proceedings of the Alzheimer Association International Conference 2014, 2016, http://www.alzheimers-and-dementia.com/article/S1552-5260(14)00370-7/fulltext%20February%2020165260(14)00370-7/fulltext.

[17] J. E. Morley, J. C. Morris, M. Berg-Weger et al., “Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference,” Journal of the American Medical Directors Association, vol. 16, no. 9, pp. 731–739, 2015.

[18] World Health Organization, Regional Office for Europe. Health promotion: A Discussion Document on the Concept and Principles : Summary Report of the Working Group on Concept and Principles of Health Promotion, WHO Regional Office for Europe, Copenhagen, Denmark, 1984.

[19] J. S. Lin et al., “Screening for cognitive impairment in older adults: an evidence update for the united states preventive services task force. evidence synthesis,” AHRQ Publication No. 14-05198-EF-1, 2013.

[20] Gerontology Society of America Workgroup on Cognitive Impairment Detection and Earlier Diagnosis. Report and Recommendations. The Gerontology Society of America, Washington, DC, USA, 2015, https://www.geron.org/images/gsa/documents/gsacworkgroup2015report.pdf.

[21] Canadian Task Force on Preventive Health Care, K. Pottie, R. Rahal et al., “Recommendations on screening for cognitive impairment in older adults,” CMAJ, vol. 188, no. 1, pp. 37–46, 2015.

[22] “United Kingdom National Screening Committee, The UK NSC recommendation on Screening for Dementia, London, Public Health England, 2015,” https://legacyscreening.phe.org.uk/dementia.

[23] J. M. G. Wilson and G. Jungner, Principles and practice of screening for disease, WHO, Geneva, Switzerland, 1968, Available from http://apps.who.int/iris/bitstream/10665/37650/17/WHO_PHP_34.pdf.

[24] L. Velayudhan, S.-H. Ryu, M. Raczek et al., “Review of brief cognitive tests for patients with suspected dementia,” International Psychogeriatrics, vol. 26, no. 8, pp. 1247–1262, 2014.

[25] M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician,” Journal of Psychiatric Research, vol. 12, no. 3, Article ID 1202204, pp. 189–198, 1975.

[26] Frequently Asked Questions, Montreal Cognitive Assessment, Montréal, Canada, 2015, http://www.mocatest.org/faq/.

[27] D. I. Kauffer, C. S. Williams, A. J. Braaten, K. Gill, S. Zimmerman, and P. D. Sloane, “Cognitive Screening for Dementia and Mild Cognitive Impairment in Assisted Living: Comparison of 3 Tests,” Journal of the American Medical Directors Association, vol. 9, no. 8, pp. 586–593, 2008.

[28] L. Flicker, D. Logiudice, J. B. Carlin, and D. Ames, “The predictive value of dementia screening instruments in clinical populations,” International Journal of Geriatric Psychiatry, vol. 12, no. 2, pp. 203–209, 1997.

[29] All Party Parliamentary Group on Dementia, Dementia Rarely Travels Alone: Living with Dementia and Other Conditions, /APPG_on_Dementia_2016_Report(2).pdf, London, UK, 2016.

[30] Alzheimer Society of Canada, “Prevalence and Monetary Costs of Dementia in Canada,” Alzheimer Society of Canada, Toronto, Canada, 2016.

[31] A. Wimo and B. Winblad, “Brain Health: A Primary Health Care Viewpoint,” Journal of the American Medical Directors Association, vol. 16, no. 9, pp. 720–721, 2015.

[32] S. Iliife and J. Wilcock, “The UK experience of promoting dementia recognition and management in primary care,” Zeitschrift für Gerontologie und Geriatrie, vol. 50, pp. 63–67, 2017.

[33] S. Bell, K. Harkness, J. M. Dickson, and D. Blackburn, “A diagnosis for £55: What is the cost of government initiatives in dementia case finding,” Age and Ageing, vol. 44, no. 2, Article ID afu205, pp. 344–345, 2015.

[34] D. Gracia, “Institute of Medicine (IOM), The Learning Healthcare System: Workshop Summary. Washington, DC: The National Academies Press, 2007,” EIDON n° 39.

[35] M. G. M. Olde Rikkert, J. A. H. R. Claassen, and R. T. C. M. Koopmans, “Do Not Harm Older Persons in Primary Care by Case Finding of Cognitive Decline, Instead Assess Cognition Only Following Loss of Well-being,” Journal of the American Medical Directors Association, vol. 17, no. 5, pp. 456–457, 2016.

[36] D. Jopp, C. Rott, and F. Oswald, “Valuation of life in old and very old age: The role of sociodemographic, social, and health resources for positive adaptation,” Gerontologist, vol. 48, no. 5, pp. 646–658, 2008.

[37] A. Steptoe, A. Deaton, and A. A. Stone, “Subjective wellbeing, health, and ageing,” The Lancet, vol. 385, no. 9968, pp. 640–648, 2015.

[38] D. Jopp and C. Rott, “Adaptation in very old age: Exploring the role of resources, beliefs, and attitudes for centenarians’ happiness,” Psychology and Aging, vol. 21, no. 2, pp. 266–280, 2006.

[39] H. Agüero-Torres, M. Kivipelto, and E. Von Strauss, “Rethinking the dementia diagnoses in a population-based study: What is Alzheimer’s disease and what is vascular dementia? A study from the Kungsholmen project,” Dementia and Geriatric Cognitive Disorders, vol. 22, no. 3, pp. 244–249, 2006.

[40] J. B. Toledo, S. E. Arnold, K. Rabile et al., “Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre,” Brain, vol. 136, no. 9, pp. 2697–2706, 2013.

[41] G. M. Savva, S. B. Wharton, P. G. Ince et al., “Age, Neuropathology, and Dementia,” The New England Journal of Medicine, vol. 360, pp. 2302–2309, 2009.

[42] Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS), “Pathological
correlates of late-onset dementia in a multicentre, community-based population in England and Wales,” *The Lancet*, vol. 357, no. 9251, pp. 169–175, 2001.

[34] D. S. Knopman, J. E. Parisi, A. Salviati et al., "Neuropathology of Cognitively Normal Elderly," *Journal of Neuropathology & Experimental Neurology*, vol. 62, pp. 1087–1095, 2003.

[35] J. A. Sonnen, E. B. Larson, P. K. Crane et al., "Pathological correlates of dementia in a longitudinal, population-based sample of aging," *Annals of Neurology*, vol. 62, no. 4, pp. 406–413, 2007.

[36] A. Hakim, *Save Your Mind: Seven Rules to Avoid Dementia*, Barlow, Toronto, Canada, 2017.

[37] D. Fitzpatrick-Lewis, R. Warren, M. U. Ali, D. Sherifi, and P. Raina, "Treatment for mild cognitive impairment: a systematic review and meta—analysis," *CMAJ Open*, vol. 3, no. 4, pp. E419–E427, 2015.

[38] A. J. Mitchell and M. Shiri-Feshki, "Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies," *Acta Psychiatrica Scandinavica*, vol. 119, no. 4, pp. 252–265, 2009.

[39] J. T. Tschanz, K. A. Welsh-Bohmer, C. G. Lyketsos et al., "Conversion to dementia from mild cognitive disorder: The Cache County Study," *Neurology*, vol. 67, no. 2, pp. 229–234, 2006.

[40] Alzheimer Society UK, *Right to Know campaign—diagnosis and support*, 2015, http://www.alzheimers.org.uk/.

[41] A. J. Mitchell and S. Malladi, "Screening and case finding tools for the detection of dementia. Part I: Evidence-based meta—analysis of multidomain tests," *American Journal of Geriatric Psychiatry*, vol. 18, no. 9, pp. 759–782, 2010.

[42] H. G. Welsh and S. Schwartz LM Woloshin, *Overdiagnosed: Making People Sick in the Pursuit of Health*, Beacon Press, Boston, MA, USA, 2011.

[43] S. Brownlee, *Overtreated: Why Too Much Medicine is Making Us Sick*, Bloomsbury, New York, NY, USA, 2008.

[44] R. Moynihan, J. Doust, and D. Henry, "Preventing overdiagnosis: how to stop harming the healthy," *The British Medical Journal*, vol. 344, no. 7859, Article ID e3502, 2012.

[45] "Harding Centre for Health Literacy, General Health Check, Max Planck Institute for Human Development,” Berlin, Germany, 2016, https://www.harding-center.mpg.de/en/health-information/fact-boxes/general-health-check.

[46] B. Winblad, P. Amouyel, S. Andrieu, and C. Ballard, "Defeating Alzheimer’s disease and other dementias: a priority for European science and society," *Lancet Neurology*, vol. 15, pp. 455–532, 2016, Accessed March 2016, http://www.thelancet.com./neurology.

[47] L. Lemieux-Charles, L. W. Chambers, R. Cockerill et al., "Evaluating the effectiveness of community-based dementia care networks: the dementia care networks’ study,” *The Gerontologist*, vol. 43, no. 4, pp. 456–464, 2003.

[48] Alzheimer’s Disease Europe, *Public beliefs on existing treatments and tests*, 2011, Accessed February 2015, http://www.alzheimer-europe.org/Research/Value-of-Knowing/Public-beliefs-on-existing-treatments-and-tests.

[49] J. Cummings, T. Morstorf, and G. Lee, "Alzheimer’s drug-development pipeline: 2016," *Alzheimer’s & Dementia: Translational Research and Clinical Interventions*, vol. 2, no. 4, pp. 222–232, 2016.

[50] C. Pimouguet, M. Lé-Goff, D. Rizzuto et al., "Effect of early referral to specialist in dementia on institutionalization and functional decline: findings from a population-based study,” *Journal of Alzheimer’s Disease*, vol. 49, pp. 819–828, 2016.